Search

Your search keyword '"Pentheroudakis G"' showing total 174 results

Search Constraints

Start Over You searched for: Author "Pentheroudakis G" Remove constraint Author: "Pentheroudakis G" Database Unpaywall Remove constraint Database: Unpaywall
174 results on '"Pentheroudakis G"'

Search Results

1. ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer

2. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer

3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

4. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review

5. Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey

6. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

8. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

9. 2107P Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients

10. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

11. Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology—shared perspectives from international consortia

12. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

13. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

14. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

15. Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit

16. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

17. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

18. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines

19. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials

20. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

21. 237P Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: A joint analysis of OnCovid and ESMO-CoCARE registries

22. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe

23. LBA70 COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases

24. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

25. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

26. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)

27. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

29. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

31. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

32. Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

33. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

34. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

35. Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

36. 1009P Current strategies of cell and gene therapy for solid tumors: Preliminary results of the joint international ESMO and EBMT Cell Therapy and Immunobiology Working Party questionnaire-based survey

37. 1567MO COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE)

38. P-173 Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: Final results of an observational study

40. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

41. 118P The clinical utility of advanced lung inflammation index (ALI) for immunotherapy guidance in non-small cell lung cancer

43. P75.04 Advanced Lung Cancer Inflammation Index (ALI), Neutrophil-to-Lymphocyte Ratio (NLR), and PD-(L)1 Inhibitor Efficacy in NSCLC

44. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

46. 1321P Advanced lung cancer inflammation index (ALI score) as a biomarker of immunotherapy efficacy in patients with advanced non-small cell lung cancer: A nationwide analysis in Greece

47. JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

50. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Catalog

Books, media, physical & digital resources